Navigation Links
Miraca Life Sciences Announces Significant American College of Gastroenterology Tradeshow Plans
Date:9/18/2013

IRVING, Texas (PRWEB) September 18, 2013

Miraca Life Sciences, the leading pathology services provider that collaborates to make patients and practices better, today announced that it will have a significant presence at the American College of Gastroenterology (ACG tradeshow), the annual scientific meeting for GI professionals October 11 – 16th in San Diego, CA.

In addition to participating in the Exhibitor Hall, Miraca will be offering an informative presentation on Meaningful Use compliance for the first 100 participants in the Exhibitor Theater on Tuesday, October 15th at 1:40 pm. At this presentation, Miraca will help GI physicians advance their workflow efficiency toward full EHR integration and offer guidance on forthcoming regulatory concerns to successfully attest to Meaningful Use requirements.

Visitors to Miraca Life Sciences’ booth, # 1015, can learn how to leverage MMR IHC testing to identify patients at risk for having Lynch Syndrome. Hereditary nonpolyposis colon cancer (HNPCC), also known as Lynch syndrome, is an inherited cancer that predisposes patients to the development of colorectal, endometrial, gastric, upper urinary tract, and other cancers. Visitors to booth # 1015 can learn how to evaluate tumors for the characteristics common to individuals with HNPCC/Lynch syndrome which include microsatellite instability and loss of protein expression of one or more of the genes associated with HNPCC/Lynch syndrome.

"Miraca has a responsibility to doctors and patients to deliver reliable, meaningful laboratory results because effective patient care stems from accurate interpretation and diagnosis, so we'll be introducing a number of exciting innovations," said Dr. Amy Noffsinger, Medical Director for Miraca Life Sciences.

In addition, seven abstracts submitted by Miraca Life Sciences’ pathologists to the American College of Gastroenterology were accepted for posters. The posters that will be presented at ACG by Miraca Life Sciences this year include:

  • Eosinophilic Esophagitis is Associated with an Increased Prevalence of Inflammatory Bowel Disease
  • Intestinal Spirochetosis is Associated with Diarrhea, Weight Loss, and Abdominal Pain in Less Than Half of the Infected Subjects: A Study of 447 Patients and 1.2 Million Controls
  • Esophageal Eosinophilia and Gastric Mucosal Pathology: Is There a Link?
  • Unexpected Candidiasis in the Endoscopically Normal Esophagus
  • Helicobacter negative Chronic Active Gastritis is a Distinct Nosologic Entity, Not Simply Missed Helicobacter Infection
  • Low Prevalence of Colon Polyps in Patients with Diarrhea and Microscopic Colitis
  • Gastric Pathology in HIV-Infected Patients

"Miraca understands every biopsy represents a patient apprehensively awaiting an answer, and Miraca believes every patient deserves the right answer. The right answer is more than a diagnosis; it is specific, accurate, sophisticated, and actionable medical information derived from collaboration by the best subspecialist pathologists," said Dr. Noffsinger. "Our 'customer first' approach is the real driver behind our innovation, and we're very excited about the many opportunities we have to showcase our new solutions in 2013."

About Miraca Life Sciences

Miraca Life Sciences specializes in the development and commercialization of the highest quality academic pathology services, primarily in the fields of dermatology, hematology, gastroenterology and urology. The company’s core team of more than 70 academic-caliber specialists utilize state-of-the-art pathology laboratories currently headquartered in Irving, Texas, and throughout the United States to serve more than 3,500 patients every day. Through rigorous quality assurance, daily and monthly conferences, and close relationships with clinical partners, Miraca Life Sciences continuously improves diagnostic precision.

About Miraca Holdings

With group net sales of ¥192.2 billion (FYE 3/2013), Miraca Holdings, a Japan-based holding company in the healthcare sector, is engaged in the business consisting of three segments: (i) development, manufacture, and commercialization of in vitro diagnostics, (ii) clinical laboratory testing, and (iii) other healthcare related businesses, which are conducted by its subsidiaries and affiliates including Fujirebio Inc,. a leading supplier of in vitro diagnostics in Japan, and SRL, Inc., Japan’s largest commercial laboratory testing services to medical institutes throughout the nation, ranging from general testing to esoteric testing, including gene-based tests.

About ACG

The American College of Gastroenterology is a recognized leader in educating GI professionals and the general public about digestive disorders. Our mission: to serve the evolving needs of physicians in the delivery of high quality scientific, humanistic and cost-effective health care to gastroenterology patients.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11092334.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Life Sciences Discovery Fund announces $3.7m in research and development grants
2. UAS LifeSciences Launches New Brand at Expo East
3. New Name, Same Commitment to Advancing the Neurological Sciences: The Movement Disorder Society (MDS) Becomes the International Parkinson and Movement Disorder Society
4. Western University of Health Sciences to Welcome More Than 1,100 New Students
5. AxoGen, Inc. to Present at the Wedbush 2013 Life Sciences Management Access Conference
6. Patheon’s Michael Lehmann Named Among PharmaVOICE 100 List of Most Inspiring People in Life Sciences Industry
7. Scott Sheldon – Specialist in Healthcare and Life Sciences Supply Chain & Official Sponsor of LogiPharma 2013
8. Market Publishers Ltd and Select Biosciences Sign Partnership Agreement
9. CMUs Kathryn Roeder to receive Outstanding Achievement by a Woman in Statistical Sciences award
10. AKA Enterprise Solutions Launches CRM and ERP Web Site for Life Sciences
11. Lauren Sciences LLC awarded second Michael J. Fox Foundation grant to further develop V-Smart™ Therapeutic for Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: